70.00GBP+2.19%Mkt Cap: 411.66M $P/E: —Today
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. The company's lead product candidate is AVA6000, a peptide drug co…
Industry Peers
Biotechnology$130.23BUSDP/E 32.1
$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$61.34BUSDP/E 39.8
$45.95BUSDP/E 19.6
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.26BUSDP/E 26.6
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
| Headline | Source | Time |
|---|---|---|
This week | ||
Older | ||
AAvacta Therapeutics | ||
AAvacta Therapeutics | ||
AAvacta Therapeutics | ||
PPanmure Liberum | ||
SShare Talk | ||
 With 75% institutional ownership, Avacta Group Plc (LON:AVCT) is a favorite amongst the big guns Key Insights Given the large stake in the stock by institutions, Avacta Group's stock price might be vulnerable to... | ||
AAvacta Therapeutics | ||
Finance week ahead: US jobs data, Nike, Tesco, Greggs and JD Wetherspoon Earnings preview of key companies reporting in the coming week and what to look out for | ||
With 83% institutional ownership, Avacta Group Plc (LON:AVCT) is a favorite amongst the big guns Key Insights Significantly high institutional ownership implies Avacta Group's stock price is sensitive to their... | ||